ArticleCancer causes & control : CCC2026
Unraveling survival disparities in primary central nervous system (CNS) lymphoma: an analysis of race, socioeconomic factors, and treatment outcomes using the surveillance, epidemiology, and end results program (2000-2021).
Article in Cancer causes & control : CCC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePrimary Central Nervous System lymphoma (PCNSL) is a rare and aggressive malignancy with variable survival outcomes. This study aimed to evaluate the impact of racial and socioeconomic disparities on survival outcomes in PCNSL and to identify independent prognostic factors using a large US population-based database.
methodsThis retrospective cohort study analyzed data from the SEER-17 database for patients diagnosed with PCNSL between 2000 and 2021. Demographic, socioeconomic, and treatment variables were extracted. Kaplan-Meier analysis assessed overall survival (OS) and cancer-specific survival (CSS) across subgroups, and multivariable Cox proportional hazards models identified independent prognostic factors.
resultsA total of 7,068 patients were included (52.3% male; mean age 63 ± 15 years). Racial composition was 63.9% Caucasian, 16.0% Hispanic, 12.2% Asian/Pacific Islander, 7.3% African American, and 0.4% American Indian/Alaskan Native. Median OS differed significantly by race (p < 0.001), ranging from 5 months in American Indian/Alaskan Natives to 22 months in Asian/Pacific Islanders. Higher income (≥ $75,000) was associated with improved median OS compared to < $50,000 (13 vs. 6 months; p < 0.001). Patients diagnosed after 2019 had markedly better outcomes (mOS 19 vs. 11 months; p = 0.001), with CSS not reached post-2019.
conclusionSignificant racial and socioeconomic disparities in PCNSL survival were identified. Higher income, chemotherapy, and radiation were independently associated with improved survival, while older age and male sex predicted worse outcomes. The improvement in outcomes after 2019 likely reflects recent advances in PCNSL management, highlighting the need for equitable access to emerging therapies.
Indexed as
Identifiers
41931176What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.